NeuroVasx Inc.
This article was originally published in Start Up
Executive Summary
NeuroVasx is taking an aggressive approach to clot removal in stroke patients. Its first product is expected to be the {xSite} catheter, a side hole drug delivery device that works by delivering drug directly into the clot.
You may also be interested in...
NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
Warning Letter Roundup & Recap – 19 January 2021
No device-related warning letters were released by the US FDA the week of 19 January.
Start-Up Spotlight: CorWave Takes Inspiration From Nature To Tackle Heart Failure
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: